Updated guidelines target co-infected HIV, TB patients


Previously published reports provided clinicians with guidelines for managing pharmacologic interactions that can result from concomitant protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) and rifamycin therapy. A group of CDC scientists and outside expert consultants recently updated the guidelines. The revised guidelines are available at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm.

Related Content
© 2024 MJH Life Sciences

All rights reserved.